Evidence map›Paper›PMID 42656984›Full record

ArticlePrecision chemistry2026

An Orally Available Derivative of a Specific CK2 Inhibitor for Regulating Circadian Rhythms and Acute Myeloid Leukemia.

Tsuyoshi Oshima, Daiki Setoyama, Akiko Sugiyama, Kazuma Amaike, Ikumi Yamanaka, Kentaro Hosokawa, Kazuto Nunomura, Kiyoshi Kawamura, Ashutosh Srivastava, Mui Iida and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Precision chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Tsuyoshi OshimaInstitute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Chikusa, Nagoya 464-8601, Japan.
Daiki SetoyamaDepartment of Clinical Laboratory, Kyushu University Hospital Fukuoka, Fukuoka 812-8582, Japan.
Akiko SugiyamaInstitute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Chikusa, Nagoya 464-8601, Japan.
Kazuma AmaikeInstitute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Chikusa, Nagoya 464-8601, Japan.
Ikumi YamanakaDepartment of Clinical Laboratory, Kyushu University Hospital Fukuoka, Fukuoka 812-8582, Japan.
Kentaro HosokawaDepartment of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University Fukuoka, Fukuoka 812-8582, Japan.
Kazuto NunomuraCenter for Supporting Drug Discovery and Life Science Research, Graduate School of Pharmaceutical Science, The University of Osaka, Suita, Osaka 565-0871, Japan.
Kiyoshi KawamuraResearch & Development, RaQualia Pharma Inc., Nakamura, Nagoya 450-0003, Japan.
Ashutosh SrivastavaInstitute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Chikusa, Nagoya 464-8601, Japan.
Mui IidaInstitute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Chikusa, Nagoya 464-8601, Japan.
Kazuhito GotohDepartment of Laboratory Medicine, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
Bangzhong LinCenter for Supporting Drug Discovery and Life Science Research, Graduate School of Pharmaceutical Science, The University of Osaka, Suita, Osaka 565-0871, Japan.
Mikio MoritaResearch & Development, RaQualia Pharma Inc., Nakamura, Nagoya 450-0003, Japan.
Masashi OhmiResearch & Development, RaQualia Pharma Inc., Nakamura, Nagoya 450-0003, Japan.
Takeshi UchiumiDepartment of Health Sciences, Graduate School of Medical Sciences, Kyushu University Fukuoka, Fukuoka 812-8582, Japan.
Fumio AraiDepartment of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University Fukuoka, Fukuoka 812-8582, Japan.
Junichi HarutaCenter for Supporting Drug Discovery and Life Science Research, Graduate School of Pharmaceutical Science, The University of Osaka, Suita, Osaka 565-0871, Japan.
Masaki SudoResearch & Development, RaQualia Pharma Inc., Nakamura, Nagoya 450-0003, Japan.
Florence TamaInstitute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Chikusa, Nagoya 464-8601, Japan.
Yuya KunisakiDepartment of Clinical Laboratory, Kyushu University Hospital Fukuoka, Fukuoka 812-8582, Japan.ORCID https://orcid.org/0000-0003-0141-7038
Kenichiro ItamiInstitute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Chikusa, Nagoya 464-8601, Japan.ORCID https://orcid.org/0000-0001-5227-7894
Tsuyoshi HirotaInstitute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Chikusa, Nagoya 464-8601, Japan.ORCID https://orcid.org/0000-0003-4876-3608

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The protein kinase CK2 controls cell cycle, apoptosis, and circadian rhythms. The CK2 inhibitor CX-4945 is in clinical trials for cancer treatment, but it has many off-target proteins. Therefore, the development of a bioavailable and specific CK2 inhibitor has been awaited. We previously discovered a specific CK2 inhibitor, GO289, from cell-based phenotypic screening of circadian clock modulators. However, the low water solubility and metabolic stability of GO289 have limited

Indexed as

acute myeloid leukemiacircadian clockCK2oral availabilitysmall-molecule compounds

Identifiers

PMID42656984
PMCPMC13508510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.